GLP-3 R

Name: GLP-3 R
Brand: Limitless Peptides
SKU: RT-10-001
Price: 210.00 USD
Availability: InStock

Purity: 99.742%

Batch #: RETA-20-601

Verified Potency: 22.18mg

$360.00

GLP-3 R is an investigational tri-agonist peptide studied for its interaction with three key receptor systems: GLP-1, GIP, and GCGR (glucagon). In research settings, it is examined for its ability to engage these pathways simultaneously, allowing scientists to explore multi-receptor activity within metabolic experimental models.

Size

3rd-Party Janoshik Verification

Ships by Calculating...

Disclaimer

For Research Use Only. Not for human consumption or therapeutic treatment.

About GLP-3 R

Retatrutide is a GGG tri-agonist peptide that targets the GLP-1 GIP and glucagon receptors. This unique receptor profile has been studied for its potential effects on metabolic processes including energy expenditure and nutrient utilization. Research has explored its role in pathways related to gastric emptying appetite regulation and the breakdown of stored energy sources highlighting its distinct approach compared to other GLP-1 receptor agonists.

Product Specifications

Retatrutide Lyophilized Powder in 3ml vial

Application

Triple agonist metabolic pathway research

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C223H343F3N46O70

CAS number

2381089-83-2

Molecular Weight

~4845.444 g/mol

FAQs

What is GLP-3 R?

GLP-3 R is a synthetic triple-agonist peptide that activates three incretin-related receptors: the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. The triple-agonist mechanism is designed to engage complementary metabolic pathways simultaneously.

What receptors does GLP-3 R activate?

GLP-3 R activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. GLP-1 receptor activation promotes insulin secretion, reduces appetite, and slows gastric emptying. GIP receptor activation enhances the incretin effect on beta cells and may influence adipose tissue metabolism. Glucagon receptor activation increases hepatic glucose output and energy expenditure. The combination of all three agonist activities in a single molecule distinguishes GLP-3 R from dual-agonist compounds.

What clinical trial data exists for GLP-3 R?

Phase 2 trial results published in the New England Journal of Medicine in 2023 reported that GLP-3 R produced dose-dependent weight loss of up to 24.2% of body weight at 48 weeks in participants with obesity. The trial enrolled 338 adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. These results exceeded the weight loss reported for approved GLP-1 receptor agonists in comparable trial designs.

How does GLP-3 R compare to GLP-1 receptor agonists?

GLP-3 R differs from GLP-1 receptor agonists like semaglutide by activating three receptors rather than one. The addition of glucagon receptor agonism is proposed to increase energy expenditure, while GIP receptor agonism enhances beta cell function and may independently affect fat metabolism. Phase 2 data showed greater weight loss at comparable timepoints than published results for semaglutide and tirzepatide, though direct head-to-head trials have not been completed.

Can I buy GLP-3 R for research?

Limitless Peptides sells GLP-3 R as a lyophilized powder in a sealed 3mL glass ampule. The product is Janoshik verified for identity, potency, and purity. GLP-3 R is sold for research use only and is not approved for human consumption. The product page includes the manufacturer's certificate of analysis and a link to the independent Janoshik verification report.

GLP-3 R

About GLP-3 R

FAQs

Related Peptides